-
Mashup Score: 0
Dosing is complete in the first cohort of the phase 1/2 clinical trial of OPGx-LCA5 for the treatment of Leber congenital amaurosis, according to a press release from Opus Genetics.
Source: www.healio.comCategories: General Medicine News, OphthalmologyTweet
Dosing is complete in the first cohort of the phase 1/2 trial of OPGx-LCA5 for the treatment of #Lebercongenitalamaurosis, in which the treatment showed signs of biological activity through 90 days. Read more from @goHealio 🔗 👇 #Retina @OpusGenetics https://t.co/sC94TvJ6nx